Ann: Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers, page-8

Aducanumab has been a complete failure and will likely be pulled from the market. Lecanemab is looking a little more promising but side effects significant - 17% of patients have brain bleeding.

Concern with Alzheimers has always been that AB buildup is the cause of the disease, however drugs that clear AB only show a modest benefit. Is this because it's 'too late, damage has been done' or is something else causing the decline? Nobody really knows yet.

Anyway, hopefully ARG may have some additional properties other than improving AB that make it more efficacious than the drugs getting approved now, and more safe!